Although the stimulating effect of insulin-like growth factor
IGF-I mediates the growth-promoting effects of GH in postnatal life, whereas IGF-II seems to be involved in the regulation of fetal growth. IGFs show mitogenie and differentiation-promoting activities in a variety of tissues in which they are produced locally and presumably act in a paracrine/autocrine manner (l-4). Both ligands interact with specific cell surface receptors, to which they bind with differing affinities. The type I IGF receptor is a heterotetramer transmembrane receptor, structurally related to the insulin receptor. It contains an intracellular tyrosine kinase domain and binds with high affinity to IGF-I and with only slightly weaker activity to IGF-II. The structurally distinct type II IGF receptor is identical to the cation-independent mannose-6-phosphate receptor (IGF-II/M6P receptor) and preferentially binds IGF-II with high affinity (5). Al-though most effects of IGF-I and IGF-II are mediated through interaction of the ligands with the type I IGF receptor, the role of the IGF-II/M6P receptor in IGF signaling remains controversial (6, 7). Furthermore, the IGFs bind to a variety of IGF-binding proteins (IGFBPs) that are present in many tissues and body fluids and take part in the regulation of IGF action (8, 9).
There are accumulating data that IGFs play an important role in the regulation of growth and differentiation of the adrenal gland. Previous studies in several species have demonstrated the presence of IGF-I/II messenger RNA (mRNA) and peptide (10-13) as well as IGF receptors in the adrenal gland (14-18). Furthermore, IGFs elicit mitogenic and differentiating effects in human adrenal cells in vitro (19) (20) (21) (22) . In bovine adrenocortical cells, IGF-I potentiates ACTH-induced cortisol secretion, upregulates ACTH receptors, and increases the mRNA abundance of various steroidogenic enzymes (15, (23) (24) (25) (26) . In the rat, however, an inhibitory role of IGF-I on steroid biosynthesis has been described (27), and IGF-II, but not IGF-I, in combination with insulin is mitogenic for fetal adrenal cells (28 
Statistics
Data are depicted as the mean 2 SEM, and differences between treatment groups were assessed by nonpaired t testing.
Results

IGF-II action in adult bovine adrenocortical cells
In time-course experiments, adult bovine adrenocortical cells were treated with IGF-I or IGF-II (13 nM) with or without the addition of ACTH (lop8 M) for up to 48 h ( Fig. 1 ). The addition of IGF-I alone (13 nM) led to a moderate increase in basal cortisol secretion, which was significant after 48 h (2.4-fold of control value; P < 0.05). In contrast, IGF-II (13 nM) stimulated basal cortisol secretion significantly after 12 h (P < O.Ol), with a 3.3-fold increase after an incubation time of led to a marked maximal 19-fold increase in basal cortisol secretion after 48 h. IGF-II (13 nM) in combination with ACTH (lo-' M) showed a synergistic stimulatory effect on cortisol secretion by primary bovine adrenocortical cells, with a 29-fold increase in cortisol levels after 48 h. A significant stimulatory effect of IGF-II on ACTH-induced cortisol secretion was observed after 12 h of incubation (3-fold increase in ACTH-induced cortisol levels; P < 0.021, and maximum cortisol levels were reached after 24 h. In contrast, IGF-I in the same concentration was significantly less effective than IGF-II at enhancing ACTH-stimulated cortisol secretion (22-fold increase), and maximum levels of cortisol were reached only after 48 h of incubation.
The stimulatory effect of IGFs on basal as well as ACTHinduced cortisol secretion was paralleled by an increase in the accumulation of CAMP in the supernatant (Fig. 2) . As expected, ACTH (lo-' M) was a potent stimulator of CAMP levels in the medium, with an increase from 2.4 to 29 pmol/ml after an incubation period of 48 1~. Maximal levels of CAMP (49.3 pmol/ml) were achieved with a combination of ACTH and IGF-II (3, 2 nM), whereas the combination of ACTH and IGF-I was significantly less potent (39.6 pmol/ ml). Treatment with IGF-II alone caused only a slight increase in CAMP and cortisol levels, and IGF-I alone had no effect. No mitogenic effect of either ligand on cell number was observed (data not shown).
Dose-response experiments with IGF-I and IGF-II in combination with ACTH showed that both ligands at very high concentrations (26-52 nM) maximally stimulated ACTH-induced cortisol secretion more than 3-fold (Fig. 3) . Additionally, an equimolar combination of both IGFs at high doses did not elicit a further stimulatory effect. However, at low concentrations (0.4-0.8 nM), IGF-I did not show any significant stimulatory effect on cortisol secretion, whereas IGF-II produced half-maximal stimulation (P < 0.005). receptor, stimulated cortisol secretion in bovine adrenal cells to a similar extent as equimolar concentrations of native IGF-II (Fig. 4) . This confirms that the effect of IGF-II on cortisol synthesis in bovine adrenocortical cells is mediated through interaction of the IGF ligands with the IGF-I and not with the IGF-II/M6P
receptor. Similar data were obtained when the cells were incubated with mutant ligands without the addition of ACTH (data not shown). To elucidate a possible modulatory role of IGFBPs on the bioactivity ofI@i;'-i'and 'RX-B 'in our ceilsystem, mutantIGF ligands with reduced affinities for IGFBPs were used (Fig. 5) 
Secretion of IGFBPs by bovine adrenocortical cells
To identify IGFBPs synthesized by adult bovine adrenocortical cells, ligand blotting of cell-conditioned medium was performed with ['25111GF-I and ['25111GF-II. As shown in Fig.  6 , the medium of untreated control cells contains at least four specific bands, with a doublet of 39-44 kDa and additional bands at 34, 29, and 24 kDa. When cells were treated with ACTH, the intensities of all bands were markedly, but differentially, increased. Quantitative analysis of the IGFBP bands of eight independent experiments indicated that in unstimulated cells, the 39-/44-kDa doublet band accounts for almost half of the detected IGFBP activity (46 t: 5%), followed by the 29-kDa (26 + 3%), the 24-kDa (15 ? 2%), and the 34-kDa (13 t was synergistic, with a 29-fold increase in basal cortisol secretion. In dose-response experiments, both IGFs at a pharmacological dose (52 nM) stimulated ACTH-induced cortisol secretion to a similar extent, and no additive effect of both ligands was observed. At physiological concentrations, however, the dose-response curve of IGF-II was significantly shifted to the left compared to that of IGF-I. IGF-II was 10 times more effective in increasing ACTH-stimulated cortisol secretion (ED,,, = 0.9 nM) than IGF-I (ED,,, = 10 nM). The observed effect of IGF-I on basal and ACTH-induced cortisol and CAMP secretion in adult bovine adrenocortical cells is in accordance to previous reports of an IGF-I-stimulated steroidogenic response in bovine (15,241, ovine (21) , and human (22) adrenal cells. In rats, however, an inhibitory effect of IGF-I on ACTH-induced steroidogenesis in isolated adrenal cells has been described (27). The only study on the effect of IGF-II on adrenal hormone secretion reports a stimulatory effect of IGF-II on ACTH-induced cortisol secretion in human fetal adrenal cells (20) . This is in good accordance with our findings in adult bovine adrenocortical cells. Our observation that IGF-II is more potent than IGF-I in stimulating bovine adrenocortical steroidogenesis supports the hypothesis that IGF-II is an important regulator of adrenocortical cell function. A predominant role of IGF-II in the autocrinel paracrine regulation of adrenal steroidogenesis has been postulated previously from a coordinate expression of IGF-II and steroidogenic enzyme mRNAs in fetal human and ovine adrenal glands (11, 35).
As we reported, bovine adrenocortical cells express both types of IGF receptors (18). However, in most cell systems the effects of both IGFs are mediated through interaction with the IGF-I receptor (2, 36). As the IGF-I receptor in our cell system exhibits a slightly higher affinity for IGF-I than for IGF-II, with a half-maximal competition for [ '2"I]IGF-I binding by 0.8 and 6.5 nM unlabeled IGF-I and IGF-II, respectively (I@, a stronger biological effect of IGF-I compared to that of IGF-II would have been expected. Therefore, the observed IO-fold stronger bioactivity of IGF-II compared to that of IGF-I is in contrast to their affinities for the IGF-I receptor. Taking into account that bovine adrenocortical cells contain far more IGF-II/M6P receptors than IGF-I receptors (18), the dose-response experiments do not allow us to assign the effect of IGF-II to a specific IGF receptor. The facts that the maximum responses of IGF-I and IGF-II were the same, and no synergistic effect by the combination of both ligands was observed provide indirect evidence that the stimulatory effect of both IGFs is mediated through the same receptor. Although the type II IGF receptor is abundant in bovine adrenocortical cells, and the concentration of unlabeled IGF-II required to displace 50% of labeled IGF-II bound to this receptor (1.8 nM) is similar to the dose of IGF-II necessary for a half-maximal stimulatory effect (0.9 nM), it is unlikely that both ligands mediate their effects through the IGF-II/ M6P receptor.
IGF (12, 24, 37) .
To further elucidate the mechanism by which IGF-II, through interaction with the IGF-I receptor, modulates the steroidogenic response to ACTH, we measured the concentration of CAMP in the culture medium. As reported previously, the increase in CAMP in the medium of intact adrenocortical cells reflects the intracellular action of adenylate cyclase due to ACTH stimulation (38). In our study we found that IGF-I and, more potently, the modulatory effect of IGFBPs in our cell system is exerted. As many IGFBPs exhibit a greater affinity for IGF-II, it is equally valid to consider the hypothesis that in this cell system, IGF-II may be preferentially bound by IGFBPs that are capable of adhering to the cell surface, thus promoting the interaction of IGF-II with the IGF-I receptor (9).
At least four different IGFBPs are synthesized by bovine adrenal cells, as assayed by Western ligand blotting of conditioned medium. The 39-44 kDa doublet detected in conditioned medium of our cell system corresponds in mol wt to different glycosylation states of IGFBP-3 and was found to be of similar size in control samples of bovine serum. Although the sizes of the 34-, 29-, and 24-kDa bands would be compatible with IGFBP-2, IGFBP-5 or -6, and IGFBP-4, respectively, the exact identification of the various bands requires further confirmation.
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